BerGenBio is a clinical-stage biopharmaceutical company developing innovative drugs for aggressive diseases including cancer and severe respiratory infections
Recent News
BerGenBio ASA: Resolution to increase the share capital for settlement of underwriting commission
BerGenBio ASA secures underwriting of NOK 118 million gross proceeds representing minimum 80% exercise of the remaining Warrants, providing funding into 2H 2025